Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-25T18:54:32.802Z Has data issue: false hasContentIssue false
  • English
  • Français

Enfermedad de Huntington: una revisión de las publicaciones sobre la prevalencia y el tratamiento de los fenomenós neuropsiquiátricos

Published online by Cambridge University Press:  12 May 2020

P. Naarding ,
H.P.H. Kremer  and
F.G. Zitman
P. Naarding
Affiliation:
Centro Médico Universitario de Nimega, Departamento de Psiquiatría, P. O. Box 9101, 6500HB Nimega, Paises Bajo
H.P.H. Kremer
Affiliation:
Centro Médico Universitario de Nimega, Departamento de Neurología, Nimega, Países
F.G. Zitman
Affiliation:
Centro Médico Universitario de Leiden, Leiden, Países Bajos
Get access

Resumen

Se realizó una revisión de las publicaciones sobre la enfermedad de Huntington, incluidas las manifestaciones neurológicas clínicas, los avances recientes en los aspectos fisiopatológicos y los mecanismos genéticos y los trastornos psicopatológicos. Se puede concluir que la investigación sobre esto último es escasa, aunque la materia es pertinente a causa de la coincidencia de fenómenos psiquiátricos, neurológicos y genéticos, lo que puede llevar a conceptos nuevos en la comprensión de la función cerebral. Hasta ahora, los intentos de proporcionar una descriptión amplia y pragmática de los trastornos psicopatológicos de la enfermedad de Huntington han sido decepcionantes, debido probablemente a las limitaciones del sistema de clasificación del DSM en este trastorno. La investigación futura debe centrarse no sólo en este sistema de clasificación, sino también en el funcionamiento neuropsicológico, a causa de la naturaleza degenerativa de la enfermedad. Se deben realizar estudios sistematicos y controlados sobre el tratamiento de las anomalías psiquiátricas en la enfermedad de Huntington antes de que se pueda extraer alguna conclusión.

Keywords

enfermedad de Huntingtonpsicopatologiapsicofarmacologiatratamiento
Type
Revisión
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 3 , April 2002 , pp. 147 - 153
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Benson, DF.Progressive frontal dysfunction. Dementia 1993;4:149-53.Google ScholarPubMed
Bhandary, ANMasand, PS.Buspirone in the management of disruptive behaviors due to Huntington’s disease and other neurological disorders. Psychosomatics 1997;38:389-91.CrossRefGoogle ScholarPubMed
Burns, AFolstein, SBrandt, JFolstein, M.Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 1990;178:20-6.CrossRefGoogle ScholarPubMed
Byrne, AMartin, WHnatko, G.Beneficial effects of buspirone therapy in Huntington’s disease. Am J Psychiatry 1994;151:1097.Google ScholarPubMed
Caine, EDHunt, RDWeingartner, HEbert, MH.Huntington’s dementia. Clinical and neuropsychological features. Arch Gen Psychiatry 1978;35:377-84.CrossRefGoogle ScholarPubMed
Caine, EDShoulson, I.Psychiatric syndromes in Huntington’s disease. Am J Psychiatry 1983;140:728-33.Google ScholarPubMed
Como, PGRubin, AJO’Brien, CFLawler, KHickey, CRubin, AE, et al.A controlled trial of fluoxetine in nondepressed patients with Huntington’s disease. Mov Disord 1997;12:397-401.CrossRefGoogle ScholarPubMed
Cummings, JLMega, MGray, KRosenberg-Thompson, SCarusi, DAGornhein, J.The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.CrossRefGoogle ScholarPubMed
Cummings, JL.Frontal-subcortical circuits and human behaviour. Arch Neurol 1993;50:873-80.CrossRefGoogle Scholar
Di Malo, LSquitieri, FNapolitano, GCampanella, GTrofatter, JAConneally, PM.Onset symptoms in 510 patients with Huntington’s disease. J Med Genet 1993;30:289-92.CrossRefGoogle Scholar
Findling, RL.Treatment of aggression in juvenile-onset Hun tington’s disease with buspirone [letter]. Psychosomatics 1993;34:460-1.CrossRefGoogle Scholar
Folstein, SAbbott, MHChase, GAJensen, BAFolstein, MR.The association of affective disorder with Huntington’s disease in a case series and in familias. Psychol Med 1983;13:537-42.CrossRefGoogle Scholar
Ford, MF.Treatment of depression in Huntington’s disease with monoamine oxidase inhibitors. BrJ Psychiatry 1986;149:654-6.CrossRefGoogle ScholarPubMed
Giel, RNienhuis, FJ.SCAN version 2.1, Dutch version in co-operation with the WHO, Genova, Switzerland. Lisse: Swets & Zeitlinger; 1999.Google Scholar
Group, THd, CRA novel gene containing a trinucleotide repeat that is expended and flnstable on Huntington’s disease chromosomes. Cell 1993;72:971-83.Google Scholar
Huntington, G.On chorea. Med Surg Rep 1872;26:317-21.Google Scholar
Lewis, CFDeQuardo, JRTandon, R.ECT in genetically confirmed Huntington’s disease. J Neuropsychiatry Clin Neurosci 1996;8:209-10.Google ScholarPubMed
Madhusoodanan, SBrenner, R.Use of risperidone in psychosis associated with Huntington’s disease [letter]. Am J Geriatr Psychiatry 1998;6:347-9.Google Scholar
Mendez, MF.Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 1994;24:189-208.CrossRefGoogle ScholarPubMed
Patel, SVTariot, PNAsnis, J.L-Deprenyl augmentation of fluoxetine in a patient with Huntington’s disease. Ann Clin Psychiatry 1996;8:23-6.CrossRefGoogle Scholar
Pflanz, SBesson, JWSEbmeier, KPSimpson, S.The clinical manifestations of mental disorder in Huntington’s disease: a retrospective case record study of disease progression. Acta Psychiatr Stand 1991;83:53-60.CrossRefGoogle Scholar
Ranen, NG, LipseyJR, Treisman, GRoss, CA.Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci 1996;8:338-40.Google ScholarPubMed
Ranen, NGPeyser, CEFolstein, SE.ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 1994;6:154-9.Google ScholarPubMed
Sajatovic, MVerbanac, P, Ramirez' LF, Meltzer, HY.Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea. Neurology 1991;41:156.CrossRefGoogle ScholarPubMed
Schoenfeld, MMyers, RHCupples, LA.Increased rafe of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 1984;47:1283-7.CrossRefGoogle Scholar
Shiwach, R.Psychopathology in Huntington’s disease patients. Acta Psychiatr Stand 1994;90:241-6.CrossRefGoogle ScholarPubMed
Shoulson, I.Huntington’s disease: cognitive and psychiatric features. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:15-22.Google Scholar
Shoulson, I.Huntington’s disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-5.CrossRefGoogle ScholarPubMed
Stewart, JTMounts, MLClark, RL.Aggressive behavior in Huntington’s disease: treatment with propranolol. J Clin Psychiatry 1987;48:106-8.Google ScholarPubMed
Stewart, JT.Huntington’s disease and propranolol [letter]. Am J Psychiatry 1993;150:166-7.Google Scholar
Weigell-Weber, MSchmid, WSpiegel, R.Psychiatric symptoms and CAG expansion in Huntington’s disease. Am J Med Genet 1996;67:53-7.Google ScholarPubMed
Whittier, JHaydu, GCrawford, MA.Effect of imipramine on depression and hyperkinesia in Huntington’s disease. Am J Psychiatry 1962;118:79.CrossRefGoogle Scholar